Proposal To Withdraw Approval for the Breast Cancer Indication for Bevacizumab; Hearing
Health and Human Services Department; Food and Drug Administration · 2011
Read Proposal To Withdraw Approval for the Breast Cancer Indication for Bevacizumab; Hearing by Health and Human Services Department; Food and Drug Administration (2011) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/uslaw-fr-2011-11539.txt.
Description
Notice published in the Federal Register on 2011-05-11 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo). [Pages 27332-27335] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-11539] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2010-N-0621] Proposal To Withdraw Approval for the Breast Cancer Indication for Bevacizumab; Hearing AGENCY: Food and Drug Administration.
Catalog record
| CREATOR | Health and Human Services Department; Food and Drug Administration |
|---|---|
| YEAR | 2011 |
| COLLECTION | LAW |
| FORMAT | TXT |
| FILE SIZE | 22 KB |
| VERSION | 1.0 |
| LICENSE | Public Domain |
| RIGHTS | PUBLIC DOMAIN |
| SOURCE | Federal Register |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Proposal To Withdraw Approval for the Breast Cancer Indication for Bevacizumab; Hearing Citation: us:fr:2011-11539 Creator: Health and Human Services Department; Food and Drug Administration Year: 2011 Source-URL: https://www.federalregister.gov/documents/2011/05/11/2011-11539/proposal-to-withdraw-approval-for-the-breast-cancer-indication-for-bevacizumab-hearing Context: Notice published in the Federal Register on 2011-05-11 by Health and Human Services Department; Food and Drug Administration. Text from federalregister.gov (official edition: govinfo). [Pages 27332-27335] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 2011-11539] ----------------------------------------------------------------------- DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2010-N-0621] Proposal To Withdraw Approval for the Breast Cancer Indication for Bevacizumab; Hearing AGENCY: Food and Drug Administration, HHS. ACTION: Notice of hearing. ----------------------------------------------------------------------- SUMMARY: The Food and Drug Administration (FDA) is granting a hearing to Genentech, Inc. (Genentech), on the Center for Drug Evaluation and Research's (CDER's) proposal to withdraw approval of the breast cancer indication for bevacizumab (Avastin). Genentech is the sponsor for Avastin. Genentech and CDER are the parties to the hearing. The issues to be discussed and resolved at the hearing relate directly to the statutory and regulatory standard for FDA to withdraw accelerated approval of the metastatic [[Page 27333]] breast cancer (MBC or breast cancer) indication for Avastin. DATES: Date and Time: The hearing will be held on June 28 and 29, 2011, from 8 a.m. to 5 p.m. ADDRESSES: The hearing will be held at FDA's White Oak Campus, 10903 New Hampshire Ave., Bldg 31, Rm. 1503 (Great Room), Silver Spring, MD 20993. FOR FURTHER INFORMATION CONTACT: Talisha Williams, Office of the Ombudsman, Office of the Commissioner, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993, 301-796-8530, e- mail: [email protected]. SUPPLEMENTARY INFORMATION: Registration and Requests to Make Oral Presentations: On June 28, 2011, up to 2 hours of the hearing have been reserved for oral presentations by persons other than the parties. If you wish to make an oral presentation during the hearing, you must register by submitting an electronic or written request by May 27, 2011, to Talisha Williams (see FOR FURTHER INFORMATION CONTACT). Depending on the number of requests, FDA may not be able to honor all such requests. You must provide your name, title, business affiliation (if applicable), address, telephone and fax numbers, e-mail address, and (if applicable) type of organization you represent (e.g., industry, consumer organization). You also should submit a brief summary of the presentation, including the discussion topic(s) that will be addressed and the approximate time requested for your presentation. We encourage individuals and organizations with common interests to consolidate or coordinate their presentations to allow adequate time for each request for presentation. If there are many requests to present during the 2- hour period, the amount of time that can be allotted to each presenter may be limited to provide an opportunity to as many persons wishing to present as possible. Persons registered to make an oral presentation should check in with Talisha Williams before the hearing. Participants should submit a copy of each presentation to Talisha Williams. We will file the hearing schedule, indicating the order of presentation and the time allotted to each person, with the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852 and it will be posted on http://www.regulations.gov. We will mail, e-mail, or telephone the schedule to each participant before the hearing. In anticipation of the hearing presentations moving ahead of schedule, participants are encouraged to arrive early to ensure their designated order of presentation. Participants who are not present when called risk forfeiting their scheduled time. If you need special accommodations due to a disability, please contact Talisha Williams at least 7 days in advance. Registration and Requests to Attend the Hearing: The public hearing is free, but all persons wishing to attend the hearing, who have not registered to make an oral presentation, must register with FDA in advance of the hearing. By May 20, 2011, FDA will post further details regarding the registration process for attendees to its Web site at http://www.fda.gov. Beginning May 27, 2011, you will be able to register to attend the hearing via FDA's Web site at http://www.fda.gov. Space in the Great Room, where the hearing is to be held, will be limited to 300 persons from the general public, and thus registration will be first-come, first-served. Web cast: The hearing will also be available to be viewed online via a Web cast. Availability of the Web cast to the public will also be limited to a certain number of persons, and registration will be required to access the Web cast. By May 20, 2011, FDA will post further details regarding the Web cast and the registration process for the Web cast to the Agency's Web site at http://www.fda.gov. Beginning May 27, 2011, you will be able to register to access the Web cast via FDA's Web site at http://www.fda.gov. Comments: Regardless of participation in the public hearing, interested persons may submit electronic or written comments on CDER's proposal to withdraw approval of the MBC indication. Submit electronic comments to http://www.regulations.gov. Submit written comments to the Division of Dockets Management (see Registration and Requests to Make Oral Presentations). Comments must be submitted by July 14, 2011. It is only necessary to send one set of comments. It is no longer necessary to send two copies of mailed comments. Identify comments with the docket number found in brackets in the heading of this document. Submission of comments prior to the meeting is strongly encouraged. All documents filed or posted in this matter are available for public review under Docket No. FDA-2010-N-0621 in the Division of Dockets Management (see Registration and Requests to Make Oral Presentations) between 9 a.m. and 4 p.m., Monday through Friday. Persons with access to the Internet may obtain documents at http://www.regulations.gov. I. Background Section 506 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 356), which was added to the statute with the passage of the Food and Drug Modernization Act of 1997, provides for the accelerated, or fast track, approval of a drug product when FDA determines that the ``* * * product has an effect on a clinical endpoint or on a surrogate endpoint that is reasonably likely to predict clinical benefit'' (section 506(b)(1)). Section 506 of the FDC&C Act also provides explicit authority for FDA to use expedited procedures to withdraw accelerated approval of a product under certain circumstances. FDA's regulations regarding the accelerated approval of biological products (Sec. Sec. 601.40 through 601.46; part 601, subpart E) (21 CFR 601.40 through 601.46; 21 CFR part 601, subpart E)) set forth the procedures that FDA uses to withdraw accelerated approval for a biological product. Under Sec. 601.43(b), FDA notifies the sponsor of the biological product of an opportunity for a hearing on a proposal to withdraw approval of the product. FDA conducts such hearings in accordance with the procedures set forth in part 15 (21 CFR part 15), with some specific modifications, including the presence of an advisory committee duly constituted under 21 CFR part 14, which provides advice and recommendations to the Agency (Sec. 601.43(e)). On February 22, 2008, under section 506 of the FD&C Act and FDA's implementing regulations